Bacterial pneumonia at King Abdulaziz University Hospital: A comparison between hospital- and community-acquired

被引:1
作者
Akbar, DH [1 ]
Ahmad, MM [1 ]
Altahawi, AT [1 ]
机构
[1] King Abdulaziz Univ Hosp, Jeddah, Saudi Arabia
关键词
pneumonia; hospital-acquired; community-acquired; causative organisms; treatment; mortality;
D O I
10.1159/000054251
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To compare community- and hospital-acquired pneumonia (CAP, HAP) with respect to causative organisms, antimicrobial susceptibility, mortality and risk factors associated with high mortality. Methods: From March 1998 to December 1999, the medical charts of patients at King Abdulaziz University Hospital older than 14 years of age with a diagnosis of pneumonia were reviewed. The following data regarding the patient's age, sex, type of pneumonia, admission to intensive care unit (ICU), type of organism isolated, antibiotic susceptibility, outcome, presence of hypotension, tachycardia, tachypnea, disturbed level of consciousness, and renal failure were recorded. Results: A total of 324 patients were studied (248 HAP, 76 CAP). Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae were the commonest isolates in CAP, while Pseudomonas spp. and Enterobacter spp. were more common in HAP. Pathogens isolated from CAP were more susceptible to ampicillin, co-amoxiclav, ciprofloxacin, cefuroxime, tetracycline and erythromycin, whereas isolates of HAP showed more sensitivity to aminoglycosides and imipenem, Mortality was higher in HAP compared to CAP: 50 versus 21%, respectively (p < 0.001). Risk factors associated with high mortality were a more advanced age, tachycardia, hypotension, a disturbed level of consciousness, renal failure and ICU admission. Conclusion: Older less expensive antibiotics can still be used in the treatment of both CAP and HAP, while the newer more expensive antibiotics should be kept in reserve to prevent the development of resistance. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:249 / 254
页数:6
相关论文
共 33 条
[1]  
ALHADRAMY MS, 1988, SAUDI MED J, V9, P34
[2]   Treatment of community-acquired pneumonia - IDSA guidelines [J].
Bernstein, JM .
CHEST, 1999, 115 (03) :9S-13S
[3]   DIAGNOSIS OF PNEUMONIA BY CULTURES, BACTERIAL AND VIRAL-ANTIGEN DETECTION TESTS, AND SEROLOGY WITH SPECIAL REFERENCE TO ANTIBODIES AGAINST PNEUMOCOCCAL ANTIGENS [J].
BURMAN, LA ;
TROLLFORS, B ;
ANDERSSON, B ;
HENRICHSEN, J ;
JUTO, P ;
KALLINGS, I ;
LAGERGARD, T ;
MOLLBY, R ;
NORRBY, R .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (05) :1087-1093
[4]  
Casellas J. M., 1999, Journal of Antimicrobial Chemotherapy, V43, P37, DOI 10.1093/jac/43.suppl_3.37
[5]   Severe community-acquired pneumonia [J].
Ewig, S ;
Torres, A .
CLINICS IN CHEST MEDICINE, 1999, 20 (03) :575-+
[6]   Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population [J].
Ewig, S ;
Kleinfeld, T ;
Bauer, T ;
Seifert, K ;
Schäfer, H ;
Göke, N .
EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (02) :370-375
[7]   Processes and outcomes of care for patients with community-acquired pneumonia - Results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study [J].
Fine, MJ ;
Stone, RA ;
Singer, DE ;
Coley, CM ;
Marrie, TJ ;
Lave, JR ;
Hough, LJ ;
Obrosky, DS ;
Schulz, R ;
Ricci, EM ;
Rogers, JC ;
Kapoor, WN .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (09) :970-980
[8]  
Fluit A C, 1999, Int J Infect Dis, V3, P153, DOI 10.1016/S1201-9712(99)90037-1
[9]   Management of community-acquired pneumonia in the era of pneumococcal resistance -: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group [J].
Heffelfinger, JD ;
Dowell, SF ;
Jorgensen, JH ;
Klugman, KP ;
Mabry, LR ;
Musher, DM ;
Plouffe, JF ;
Rakowsky, A ;
Schuchat, A ;
Whitney, CG .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (10) :1399-1408
[10]   A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome [J].
Hoepelman, IM ;
Mollers, MJ ;
van Schie, MH ;
Greefhorst, APM ;
Schlosser, NJJ ;
Damste, EJS ;
van de Moosdijk, CNF ;
Dalinghaus, WH ;
Eland, ME ;
Mol, SJM ;
Rozenberg-Arska, M .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1998, 9 (03) :141-146